Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: J Thromb Haemost. 2018 Mar 13;16(4):670–679. doi: 10.1111/jth.13974

Table 2.

Hazard ratios (95% CIs) of incident VTE after AF, for overall VTE and by VTE type: The Atherosclerosis Risk in Communities Study, 1987-2011

No AF (n=13,081) AF (n=2048)
VTE (n = 681)
# Events 613 68
Person-years 259,659 10,759
Incidence Rate (95% CI)* 2.4 (2.2-2.6) 6.3 (4.9-8.0)
Hazard ratio (95% CI)
 Model 1 1 (REF) 2.02 (1.56-2.61)
 Model 2 1 (REF) 1.71 (1.32-2.22)
 Model 3 1 (REF) 1.88 (1.44-2.45)
PE (without DVT) (n = 190)
# Events 173 17
Incidence Rate (95% CI)* 0.7 (0.6-0.8) 1.6 (0.96-2.5)
Hazard ratio (95% CI)
 Model 1 1 (REF) 1.59 (0.96-2.64)
 Model 2 1 (REF) 1.41 (0.85-2.36)
 Model 3 1 (REF) 1.47 (0.86-2.52)
Any DVT (n = 491)
# Events 440 51
Incidence Rate (95% CI)* 1.7 (1.5-1.9) 4.7 (3.6-6.2)
Hazard ratio (95% CI)
 Model 1 1 (REF) 2.23 (1.65-3.00)
 Model 2 1 (REF) 1.86 (1.37-2.51)
 Model 3 1 (REF) 2.07 (1.52-2.81)
*

Incidence rate is per 1000 person-years.

Includes events presenting as DVT alone, and those presenting as both DVT and PE.

CI, confidence interval; VTE, venous thromboembolism; AF, atrial fibrillation; DVT, deep vein thrombosis.

Model 1 is adjusted for age, sex and race-field center.

Model 2: Model 1+ income, education, physical activity, smoking, waist circumference, height, systolic blood pressure, anti-hypertensive medication, diabetes, prevalent coronary heart disease, prevalent heart failure, prevalent anticoagulant use and eGFR.

Model 3: Model 2 + time-dependent anticoagulant use.

HHS Vulnerability Disclosure